Covered recipient · General Payments record
KARNG S LOG
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$2,288.77
37 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $1,170.00 | 1 |
| Food and Beverage | $1,005.60 | 32 |
| Education | $113.17 | 4 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Scientific Affairs, LLC | $1,187.86 | 2 |
| E.R. Squibb & Sons, L.L.C. | $226.04 | 5 |
| CTI BioPharma Corp. | $148.78 | 2 |
| Karyopharm Therapeutics Inc. | $114.52 | 1 |
| SOBI, INC | $69.99 | 1 |
| Amgen Inc. | $59.43 | 3 |
| Merck Sharp & Dohme LLC | $49.28 | 3 |
| PFIZER INC. | $43.38 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $33.57 | 2 |
| Regeneron Healthcare Solutions, Inc. | $30.76 | 1 |
| Sumitomo Pharma America, Inc. | $26.85 | 1 |
| AVEO Pharmaceuticals, Inc. | $26.80 | 1 |
| Pharmacosmos Therapeutics Inc. | $26.59 | 1 |
| Mirati Therapeutics, Inc. | $25.50 | 1 |
| Exelixis Inc. | $24.13 | 1 |
| GlaxoSmithKline, LLC. | $22.56 | 1 |
| GENZYME CORPORATION | $21.75 | 1 |
| AstraZeneca Pharmaceuticals LP | $20.03 | 1 |
| Lilly USA, LLC | $20.03 | 1 |
| TerSera Therapeutics LLC | $19.55 | 1 |
| Janssen Biotech, Inc. | $19.52 | 1 |
| ARRAY BIOPHARMA INC | $19.23 | 1 |
| Incyte Corporation | $19.14 | 1 |
| Seagen Inc. | $17.80 | 1 |
| Celgene Corporation | $15.68 | 1 |
Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KARNG S LOG
NPI 1932310034 · CMS profile ID 224047
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LITTLETON, CO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1932310034?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KARNG S LOG, NPI 1932310034, CMS profile ID 224047. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932310034?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). KARNG S LOG, NPI 1932310034, CMS profile ID 224047. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932310034?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- KARNG S LOG, NPI 1932310034, CMS profile ID 224047, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1932310034?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
37 matching records · $2,288.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–37 of 37.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celgene Corporation | $15.68 | 10/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014797643 | CMS |
| ARRAY BIOPHARMA INC | $19.23 | 10/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049183853 | CMS |
| Incyte Corporation | $19.14 | 09/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044569367 | CMS |
| GENZYME CORPORATION | $21.75 | 09/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049877385 | CMS |
| Mirati Therapeutics, Inc. | $25.50 | 08/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057996437 | CMS |
| Exelixis Inc. | $24.13 | 08/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044587811 | CMS |
| SOBI, INC | $69.99 | 07/31/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038126109 | CMS |
| PFIZER INC. | $25.00 | 07/28/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049587081 | CMS |
| Seagen Inc. | $17.80 | 07/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995649611 | CMS |
| Amgen Inc. | $16.81 | 07/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020613639 | CMS |
| TerSera Therapeutics LLC | $19.55 | 07/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1052418989 | CMS |
| Pharmacosmos Therapeutics Inc. | $26.59 | 07/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1046254915 | CMS |
| E.R. Squibb & Sons, L.L.C. | $70.13 | 06/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014797373 | CMS |
| Merck Sharp & Dohme LLC | $18.81 | 06/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048570171 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.09 | 06/28/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014797301 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.09 | 06/28/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014797701 | CMS |
| Merck Sharp & Dohme LLC | $16.99 | 06/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048928601 | CMS |
| Amgen Inc. | $26.59 | 05/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019985349 | CMS |
| Janssen Scientific Affairs, LLC | $1,170.00 | 05/23/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988543603 | CMS |
| Lilly USA, LLC | $20.03 | 05/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031847571 | CMS |
| GlaxoSmithKline, LLC. | $22.56 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003380217 | CMS |
| Merck Sharp & Dohme LLC | $13.48 | 04/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048824123 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.03 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016059847 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.65 | 04/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055460161 | CMS |
| CTI BioPharma Corp. | $23.78 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1039692315 | CMS |
| Karyopharm Therapeutics Inc. | $114.52 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056903443 | CMS |
| Janssen Scientific Affairs, LLC | $17.86 | 03/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988543609 | CMS |
| CTI BioPharma Corp. | $125.00 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1039692319 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.16 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014796871 | CMS |
| Sumitomo Pharma America, Inc. | $26.85 | 03/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1030859937 | CMS |
| PFIZER INC. | $18.38 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049390151 | CMS |
| Regeneron Healthcare Solutions, Inc. | $30.76 | 02/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999278161 | CMS |
| E.R. Squibb & Sons, L.L.C. | $115.57 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014796931 | CMS |
| AVEO Pharmaceuticals, Inc. | $26.80 | 01/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049061307 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.92 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055460155 | CMS |
| Amgen Inc. | $16.03 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019985347 | CMS |
| Janssen Biotech, Inc. | $19.52 | 01/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988327905 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $315,969.88 | 14 |
| PY2024 | Principal investigator | $24,802.39 | 5 |
| PY2023 | Principal investigator | $787.80 | 2 |
| PY2022 | Principal investigator | $49,206.20 | 13 |
| PY2021 | Principal investigator | $30,362.94 | 10 |
| PY2020 | Principal investigator | $18,487.66 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
14 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,386.72 | 12/31/2025 | Non-covered Recipient Entity Exempla Lutheran Medical Center | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat MK-3543 versus Hydroxyurea in Cytoreductive Therapy Na ve Essential Thrombocythemia Participants | No dispute reported | 06/30/2026 | 1232928724 |
| Principal investigator 1 | PFIZER INC. | $3,640.00 | 12/31/2025 | Non-covered Recipient Entity Sisters of Charity of Leavenworth Health System Inc | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228747237 |
| Principal investigator 1 | AstraZeneca UK Limited | $79,729.00 | 12/17/2025 | Non-covered Recipient Entity INTERMOUNTAIN HEALTHCARE | a phase 2,open label study to evaluate the safety,tolerability,pharmacokinetics,immunogenicity,and antitumor activity of volrustomig priming regimen in combination with other anticancer agents in participants with solid tumors evolve 01 | No dispute reported | 06/30/2026 | 1185546593 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 12/09/2025 | Non-covered Recipient Entity Lutheran Hospital Cancer Centers of Colorado | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228711982 |
| Principal investigator 1 | PFIZER INC. | $27,110.00 | 11/26/2025 | Non-covered Recipient Entity Sisters of Charity of Leavenworth Health System Inc | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228720157 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 11/18/2025 | Non-covered Recipient Entity Lutheran Hospital Cancer Centers of Colorado | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228711980 |
| Principal investigator 1 | PFIZER INC. | $16,330.08 | 11/18/2025 | Non-covered Recipient Entity Lutheran Hospital Cancer Centers of Colorado | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712052 |
| Principal investigator 1 | ABBVIE INC. | $13,250.00 | 11/06/2025 | Non-covered Recipient Entity SISTERS OF CHARITY OF LEAVENWORTH | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202523437 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $76,858.32 | 08/31/2025 | Non-covered Recipient Entity Exempla Lutheran Medical Center | A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1232923890 |
| Principal investigator 1 | PFIZER INC. | $3,154.20 | 05/19/2025 | Non-covered Recipient Entity Lutheran Medical Center Red Rocks | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228717491 |
| Principal investigator 1 | PFIZER INC. | $3,154.20 | 05/19/2025 | Non-covered Recipient Entity Lutheran Medical Center Red Rocks | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228758767 |
| Principal investigator 1 | ABBVIE INC. | $33,850.00 | 01/09/2025 | Non-covered Recipient Entity SCL HEALTH RESEARCH INSTITUTE INC | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202437566 |
| Principal investigator 1 | ABBVIE INC. | $33,850.00 | 01/09/2025 | Non-covered Recipient Entity SISTERS OF CHARITY OF LEAVENWORTH | M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202437641 |
| Principal investigator 1 | AstraZeneca UK Limited | $21,627.36 | 01/09/2025 | Non-covered Recipient Entity INTERMOUNTAIN HEALTHCARE | an observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD | No dispute reported | 06/30/2026 | 1185546596 |